Cited by

• Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta-analysis.

  Wu H, Ding X, Zhang Y, Li W, Chen J. Wu H, et al. J Clin Hypertens (Greenwich). 2022 Jun;24(6):667-676. doi: 10.1111/jch.14463. Epub 2022 May 10. J Clin Hypertens (Greenwich). 2022. PMID: 35538636 Free PMC article.
• Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.

  Lengel D, Lamm Bergström E, Barthlow H, Oldman K, Musgrove H, Harmer A, Valentin JP, Duffy P, Braddock M, Curwen J. Lengel D, et al. Pharmacol Res Perspect. 2015 Oct;3(5):e00176. doi: 10.1002/prp2.176. Epub 2015 Sep 15. Pharmacol Res Perspect. 2015. PMID: 26516588 Free PMC article.
• Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

  Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Demetri GD, et al. Clin Cancer Res. 2009 Sep 15;15(18):5902-9. doi: 10.1158/1078-0432.CCR-09-0482. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737946 Free PMC article. Clinical Trial.
• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Dahlberg SE, et al. J Clin Oncol. 2010 Feb 20;28(6):949-54. doi: 10.1200/JCO.2009.25.4482. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085937 Free PMC article. Clinical Trial.
• Targeted therapies in renal cell cancer: recent developments in imaging.

  van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. van der Veldt AA, et al. Target Oncol. 2010 Jun;5(2):95-112. doi: 10.1007/s11523-010-0146-5. Epub 2010 Jul 14. Target Oncol. 2010. PMID: 20625845 Free PMC article. Review.